Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little

Jerome R Hoffman
Med J Aust 2003; 179 (7): . || doi: 10.5694/j.1326-5377.2003.tb05584.x
Published online: 6 October 2003

Has enthusiasm overwhelmed judgement?

Although advocates of the use of tissue plasminogen activator (tPA) in acute ischaemic stroke suggest that this “is one of the most important advances in stroke medicine”,1 a recent Cochrane meta-analysis also supports “clinicians who choose . . . not to use the treatment at all”,2 and all three major emergency medicine associations in North America have declined to endorse it as “standard of care”.3

  • Jerome R Hoffman

  • School of Medicine, UCLA, Los Angeles, California, USA.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.